Beeline Medicines is a clinical-stage biotechnology company building a focused pipeline of precision therapies rooted in validated biology. Its lead candidate, afimetoran, is a once-daily oral small molecule that targets toll-like receptors 7 and 8 (TLR7/8). Afimetoran has completed a Phase 1b trial in cutaneous lupus erythematosus and is currently in a Phase 2 study with a readout expected by year-end. The company plans to initiate a pivotal lupus trial following the Phase 2 results. Beeline emerged from stealth concurrent with announcing a $300M Series A financing led by Bain Capital. The company emphasizes durable, meaningful outcomes for patients with significant unmet needs and has assembled a leadership team that includes CEO Saqib Islam, COO and President Badreddin Edris, and CMO Nathalie Franchimont.

Total raised

$426M

Funding rounds

2

Latest round

Series A

Latest activity

Jun 2026